Table 3.

Management of hypertension in AAD and control patients

	Total			Type A			Type B
	Control	AAD	P value	Control	AAD	P value	Control	AAD	P value
Patients	848	585		388	265		460	320
Male, n (%)	578 (68.2)	376 (64.3)	0.125	261 (67.3)	171 (64.5)	0.468	317 (68.9)	205 (64.1)	0.157
Age, mean (SD)	56.8 (11.3)	57.3 (12.0)	0.379	57.1 (11.2)	57.4 (12.5)	0.748	56.6 (11.)	57.3 (11.7)	0.365
Year of history, median (IQR)	8 (4‐10)	10 (5‐12)	<0.001	8 (4‐10)	10 (5‐12)	0.015	8 (4‐10)	10 (5‐12)	0.014
Stage of hypertension*
Stage 1	80 (9.4)	40 (6.8)		40 (10.3)	19 (7.2)		40 (8.7)	21 (6.6)
Stage 2	218 (25.7)	122 (20.9)a		95 (24.5)	52 (19.6)		123 (26.7)	71 (22.2)
Stage 3	550 (64.9)	422 (72.1)a	<0.001b	253 (65.2)	194 (73.2)a	0.028b	297 (64.6)	228 (71.3)	0.048b
Management of hypertension
Regular treated	598 (70.5)	278 (47.5)a		279 (71.9)	126 (47.5)a		319 (69.3)	152 (47.5)a
Irregular treated	179 (21.1)	231 (39.4)a		79 (20.4)	103 (38.9)a		100 (21.7)	128 (40)a
Never treated	71 (8.4)	76 (13.0)a	<0.001b	30 (7.7)	36 (13.6)a	<0.001b	41 (8.9)	40 (12.5)	<0.001b
Uncontrolled hypertension	393 (46.3)	422 (72.1)	<0.001	179 (46.1)	194 (73.2)	<0.001	214 (46.5)	228 (71.3)	<0.001

Continuous variables were compared with a two‐sample t test or Wilcoxon signed‐rank test. Categorical variables were compared with the chi‐square test. The ordinal categorical variable was compared with the Kruskal‐Wallis test. Wilcoxon signed‐rank test was used if a difference between groups was observed. Uncontrolled hypertension, hypertensive patients with uncontrolled blood pressure (SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg).

^*The stage of hypertension was based on JNC6.

^a P < 0.05 comparing with the control group, for exact P value, please refer to Table S3.

^bWilcoxon signed‐rank test.